Blog
RSS FeedPosted by Michael Wonder on 29 Jan 2019
Proposal for changes to funded haemophilia treatments
29 January 2019 - PHARMAC is proposing to make changes to the funding of haemophilia treatments from 1 May 2019, ...
Posted by Michael Wonder on 22 Jan 2019
PHARMAC publishes PTAC outcome for nivolumab in renal cell carcinoma
22 January 2019 - The Committee reviewed the application for nivolumab for the second-line treatment of relapsed clear cell renal ...
Posted by Michael Wonder on 22 Jan 2019
PTAC recommends Keytruda for patients with non-small cell lung cancer
22 January 2019 - PTAC reviewed an application from Merck Sharpe and Dohme for the funding of pembrolizumab in combination ...
Posted by Michael Wonder on 11 Jan 2019
Notification of decision involving treatments for multiple sclerosis, narcolepsy, and attention deficit hyperactivity disorder
11 January 2019 - PHARMAC is pleased to announce the approval of a multi-product agreement with Teva Pharma New Zealand ...
Posted by Michael Wonder on 10 Jan 2019
Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
10 January 2019 - PHARMAC is pleased to announce its decision to approve a multi-product agreement with Merck Sharpe & ...
Posted by Michael Wonder on 17 Dec 2018
PHARMAC funding decision gives Kiwis with hepatitis C access to a potential cure
17 December 2018 - Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February ...
Posted by Michael Wonder on 17 Dec 2018
Decision to fund a new hepatitis C treatment (Maviret) and to widen access to adalimumab (Humira) for psoriasis
17 December 2018 - PHARMAC is pleased to announce a decision to fund a new treatment for chronic hepatitis C ...
Posted by Michael Wonder on 14 Dec 2018
Decision in relation to infliximab, tocilizumab and rituximab
14 December 2018 - PHARMAC is pleased to announce a decision on how three hospital medicines (infliximab, tocilizumab and rituximab) ...
Posted by Michael Wonder on 23 Oct 2018
NZ patients with ALK positive non-small-cell lung cancer score a minor win
23 October 2018 - PTAC has recommended that alectinib hydrochloride be funded for the first-line treatment of ALK positive, locally ...
Posted by Michael Wonder on 28 Sep 2018
Decision to fund sapropterin
28 September 2018 - PHARMAC is pleased to announce a decision to list sapropterin (Kuvan), a treatment for the rare ...
Posted by Michael Wonder on 12 Sep 2018
Decision to list nintedanib (Ofev) and remove restrictions from tiotropium bromide (Spiriva)
12 September 2018 - PHARMAC is pleased to announce a decision to list nintedanib (Ofev) and remove the current Special ...
Posted by Michael Wonder on 06 Sep 2018
Approval of multi-product funding agreement with Novartis
6 September 2018 - PHARMAC is pleased to announce a major funding package involving ten medicines in seven key therapy ...
Posted by Michael Wonder on 06 Sep 2018
New agreement makes more medicines available to treat range of health conditions
6 September 2018 - Up to 50,000 New Zealanders per year will benefit from a new multiproduct agreement PHARMAC has ...
Posted by Michael Wonder on 29 Jul 2018
PTAC defers submission for new indication for PD-L1 antagonist
27 July 2018 - This time its for patients with Hodgkin's disease. The reason; PTAC wants to see updated data ...
Posted by Michael Wonder on 26 Jul 2018
PTAC recommends immune checkpoint inhibitors for certain patients with advanced urothelial carcinoma
25 July 2018 - The publication of the minutes of the May 2018 PTAC meeting reveals new outcomes. ...